Skip to main content
Dryad logo

Data from: Prospective validation of the PML risk biomarker L-Selectin and influence of natalizumab extended intervals

Citation

Schwab, Nicholas; Schneider-Hohendorf, Tilman (2019), Data from: Prospective validation of the PML risk biomarker L-Selectin and influence of natalizumab extended intervals, Dryad, Dataset, https://doi.org/10.5061/dryad.cq0nt70

Abstract

Low L-selectin (CD62L) on CD4+ T cells after cryopreservation has been introduced in 2013 as a risk biomarker for the development of progressive multifocal leukoencephalopathy (PML) during natalizumab treatment1 or HIV infection.2 The biomarker has been reproduced retrospectively in some international cohorts,3,4 but not in others,5 potentially because of its sensitivity to biomaterial quality, assay protocols, and the time point of testing. With regard to current approaches to PML risk reduction, natalizumab extended interval dosing is thought to improve immune surveillance and reduce PML risk, whereas clinical efficacy seems unaffected.6

Usage Notes